The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma | Zendy

María del Carmen López Castillo | Zendy; Fabián Andrés Rosas Romero | Zendy; Esther Argüello | Zendy; Chrisann Kyi | Zendy; Michael A. Postow | Zendy; Gil RedelmanSidi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

Author(s) -

María del Carmen López Castillo,

Fabián Andrés Rosas Romero,

Esther Argüello,

Chrisann Kyi,

Michael A. Postow,

Gil RedelmanSidi

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw539

Subject(s) - medicine , blockade , immune checkpoint , pembrolizumab , melanoma , nivolumab , retrospective cohort study , infliximab , immune system , oncology , immunology , immunotherapy , tumor necrosis factor alpha , cancer research , receptor

The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research